Guobang Pharma H1 2026 profit drops 25.07% despite 3.84% revenue growth

Operating cash flow jumped 342.23% as foreign exchange losses and a 37.75% rise in selling expenses weighed on earnings.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.